2023 World Conference on Lung Cancer (Posters)-P2.10. Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L

P2.10. Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L - PDF(Slides)

Back to course

Pdf Summary

The ALTA-1L trial compared the efficacy of brigatinib and crizotinib in patients with ALK non-small cell lung cancer (NSCLC) who were ALK inhibitor-naive. The trial showed that brigatinib had a longer median progression-free survival (PFS) compared to crizotinib. Additionally, brigatinib demonstrated significant improvement in health-related quality of life (HRQoL) compared to crizotinib.<br /><br />This study aimed to compare the time to worsening (TTW) in HRQoL scores between responders and nonresponders to brigatinib and crizotinib. The analysis included patients in the intention-to-treat (ITT) patient-reported outcomes (PRO) population who had available data for clinical response and HRQoL.<br /><br />The results showed that responders to brigatinib and crizotinib had significantly longer median TTW in global health status/quality of life (GHS/QoL) compared to nonresponders. Furthermore, brigatinib responders had a lower likelihood of experiencing worsening in multiple HRQoL domains, including physical functioning, dyspnea, insomnia, and appetite loss, compared to nonresponders. Crizotinib responders also had a lower likelihood of experiencing worsening in several HRQoL domains, including physical functioning, emotional functioning, cognitive functioning, pain, dyspnea, and the QLQ-C30 summary score, compared to nonresponders.<br /><br />Additionally, there was a correlation between a longer duration of response (DoR) and longer TTW in certain HRQoL domains for brigatinib responders compared to crizotinib responders.<br /><br />In conclusion, responders to brigatinib and crizotinib had improved HRQoL outcomes compared to nonresponders. Brigatinib responders, in particular, had a lower likelihood of experiencing worsening events and significant delays in TTW in various HRQoL domains. These findings suggest that brigatinib may provide better quality of response and improved HRQoL compared to crizotinib for patients with ALK NSCLC.

Asset Subtitle

Rosario García-Campelo

Meta Tag

Speaker Rosario García-Campelo

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

ALTA-1L trial

brigatinib

crizotinib

ALK non-small cell lung cancer

progression-free survival

health-related quality of life

time to worsening

responders

nonresponders

duration of response